253 related articles for article (PubMed ID: 25912930)
1. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J
Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930
[TBL] [Abstract][Full Text] [Related]
2. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
[TBL] [Abstract][Full Text] [Related]
3. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
5. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
6. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
[TBL] [Abstract][Full Text] [Related]
7. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).
Mitchell K; Steidl U
Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31451539
[TBL] [Abstract][Full Text] [Related]
8. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
10. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
11. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
12. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
[TBL] [Abstract][Full Text] [Related]
15. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
[TBL] [Abstract][Full Text] [Related]
16. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
17. Preferential induction of apoptosis for primary human leukemic stem cells.
Guzman ML; Swiderski CF; Howard DS; Grimes BA; Rossi RM; Szilvassy SJ; Jordan CT
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16220-5. PubMed ID: 12451177
[TBL] [Abstract][Full Text] [Related]
18. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
19. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW
Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961
[TBL] [Abstract][Full Text] [Related]
20. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
